Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine ... Royalty Pharma's current portfolio includes royalties on more than 35 commercial ...

Dr. Coric's background includes leading Biohaven to the successful FDA approval and market launch of Nurtec ODT for migraine treatment ... Royalty Pharma's portfolio boasts royalties on over 35 ...

The girl told police she was dropped off by her mother and was not sure if she was going to return The parents of a 6-year-old girl who was seen wandering alone with a dog in Deltona, Fla., ...

Dr. Coric's background includes leading Biohaven to the successful FDA approval and market launch of Nurtec ODT for migraine ... boasts royalties on over 35 commercial products and 15 development ...

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of ... includes royalties on more than 35 commercial products, including Vertex’s Trikafta ...

Although the company will lose patent exclusivity for several top drugs, it also has newer products on the market, such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT ...